447 related articles for article (PubMed ID: 31400383)
21. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
Gholizadeh S; Dolman EM; Wieriks R; Sparidans RW; Hennink WE; Kok RJ
Pharm Res; 2018 Mar; 35(4):85. PubMed ID: 29516187
[TBL] [Abstract][Full Text] [Related]
22. Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment.
Jin Y; Yang F; Du L
Colloids Surf B Biointerfaces; 2013 Dec; 112():421-8. PubMed ID: 24036626
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel.
Li X; Tian X; Zhang J; Zhao X; Chen X; Jiang Y; Wang D; Pan W
Int J Nanomedicine; 2011; 6():1167-84. PubMed ID: 21852896
[TBL] [Abstract][Full Text] [Related]
24. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer.
Mi Y; Zhao J; Feng SS
J Control Release; 2013 Aug; 169(3):185-92. PubMed ID: 23403395
[TBL] [Abstract][Full Text] [Related]
25. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
26. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs.
Crosasso P; Brusa P; Dosio F; Arpicco S; Pacchioni D; Schuber F; Cattel L
J Pharm Sci; 1997 Jul; 86(7):832-9. PubMed ID: 9232525
[TBL] [Abstract][Full Text] [Related]
27. Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft.
Fontaine SD; Hann B; Reid R; Ashley GW; Santi DV
Cancer Chemother Pharmacol; 2019 Oct; 84(4):729-738. PubMed ID: 31321449
[TBL] [Abstract][Full Text] [Related]
28. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids.
Jensen SS; Andresen TL; Davidsen J; Høyrup P; Shnyder SD; Bibby MC; Gill JH; Jørgensen K
Mol Cancer Ther; 2004 Nov; 3(11):1451-8. PubMed ID: 15542784
[TBL] [Abstract][Full Text] [Related]
29. Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer.
Yan J; Wang Y; Jia Y; Liu S; Tian C; Pan W; Liu X; Wang H
Biomed Pharmacother; 2017 Apr; 88():374-383. PubMed ID: 28122302
[TBL] [Abstract][Full Text] [Related]
30. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
32. Antitumor efficiency of D-alpha-tocopheryl polyethylene glycol 1000 succinate-b-poly(epsilon-caprolactone-ran-lactide) nanoparticle-based delivery of docetaxel in mice bearing cervical cancer.
Wang Z; Zeng X; Ma Y; Liu J; Tang X; Gao Y; Liu K; Zhang J; Ming P; Huang L; Mei L
J Biomed Nanotechnol; 2014 Aug; 10(8):1509-19. PubMed ID: 25016651
[TBL] [Abstract][Full Text] [Related]
33. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
[TBL] [Abstract][Full Text] [Related]
34. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
[TBL] [Abstract][Full Text] [Related]
35. Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery.
Zhai G; Wu J; Xiang G; Mao W; Yu B; Li H; Piao L; Lee LJ; Lee RJ
J Nanosci Nanotechnol; 2009 Mar; 9(3):2155-61. PubMed ID: 19435095
[TBL] [Abstract][Full Text] [Related]
36. Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity.
Chu KS; Finniss MC; Schorzman AN; Kuijer JL; Luft JC; Bowerman CJ; Napier ME; Haroon ZA; Zamboni WC; DeSimone JM
Nano Lett; 2014 Mar; 14(3):1472-6. PubMed ID: 24552251
[TBL] [Abstract][Full Text] [Related]
37. Design and preparation of pH-sensitive cytotoxic liposomal formulations containing antitumor colchicine analogues for target release.
Shchegravina ES; Tretiakova DS; Sitdikova AR; Usova SD; Boldyrev IA; Alekseeva AS; Svirshchevskaya EV; Vodovozova EL; Fedorov AY
J Liposome Res; 2024 Sep; 34(3):399-410. PubMed ID: 37867342
[TBL] [Abstract][Full Text] [Related]
38. Self-Assembly of pH-Labile Polymer Nanoparticles for Paclitaxel Prodrug Delivery: Formulation, Characterization, and Evaluation.
Levit SL; Gade NR; Roper TD; Yang H; Tang C
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291475
[TBL] [Abstract][Full Text] [Related]
39. Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.
Patel K; Doddapaneni R; Sekar V; Chowdhury N; Singh M
Mol Pharm; 2016 Jun; 13(6):2049-58. PubMed ID: 27070720
[TBL] [Abstract][Full Text] [Related]
40. Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.
Wu R; Zhang Z; Wang B; Chen G; Zhang Y; Deng H; Tang Z; Mao J; Wang L
Drug Des Devel Ther; 2020; 14():2249-2261. PubMed ID: 32606595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
